Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

GSK's Jideytro (zidesamtinib) wins FDA approval for ROS1-positive metastatic non-small cell lung cancer
Small molecule, cancer, kinase inhibitor, non-small cell lung cancer, ROS1 mutation - Read more

Takeda China wins NMPA approval for Orzeyful (oveporexton), first OX2R agonist treating narcolepsy type 1, based on Ph3 data
Small molecule, neurological, orexin receptor agonist, narcolepsy type 1, orexin deficiency - Read more

Haisco Pharmaceutical's Ciprocopan (ciprocopan succinate) wins NMPA approval for paroxysmal nocturnal hemoglobinuria as first oral complement factor B inhibitor
Small molecule, hematological disease, complement inhibitor, paroxysmal nocturnal hemoglobinuria, complement factor B - Read more

AstraZeneca's Etcamah (camizestrant) wins EU approval for oestrogen receptor-positive, HER2-negative advanced breast cancer after Ph3 success
Small molecule, cancer, oral SERD, breast cancer, ESR1 mutation, CDK4/6 inhibitor - Read more

Nona Biosciences, Medical University of Vienna collaborate on fully human antibody development for infectious diseases
Research collaboration, infectious disease, antibody, drug discovery- Read more

Arcus Biosciences, AVEO Oncology partner to evaluate casdatifan plus tivozanib in advanced kidney cancer
Clinical supply agreement, oncology, small molecule, co-development - Read more

Arcus Biosciences, Summit Therapeutics collaborate to evaluate casdatifan plus ivonescimab combination in kidney cancer
Clinical trial collaboration, oncology, small molecule, antibody, renal cell carcinoma - Read more

Whether you’re working in genomics, imaging, or research, the key to innovation is fast, seamless access to your data–anywhere you need it. 

Qumulo Cloud Data Fabric unifies distributed data into a single global namespace, enabling teams to collaborate and access the same data from anywhere. 

Learn how Qumulo is putting infrastructure at the cutting edge of pharma and medical research. Explore the solution here.

J&J's Tecvayli (teclistamab) and Talvey (talquetamab) combo cuts multiple myeloma progression risk 89% in Ph3
Antibody, cancer, bispecific antibody, multiple myeloma, BCMA, GPRC5D - Read more

Eli Lilly's (retatrutide) hits Ph3 primary endpoints with 22.6% weight loss in obesity with cardiovascular disease
Small molecule, metabolic, GLP-1 receptor agonist, obesity, type 2 diabetes, cardiovascular risk - Read more

Arrowhead Pharmaceuticals' (plozasiran) Ph3 trials show up to 81% triglyceride reduction in severe hypertriglyceridemia patients
Small molecule, metabolic, siRNA, hypertriglyceridemia, triglyceride reduction, acute pancreatitis - Read more

Summit Therapeutics, Akeso's (ivonescimab) Ph3 Western data show 24% lower death risk in EGFR-mutated non-small cell lung cancer
Antibody, cancer, bispecific antibody, non-small cell lung cancer, PD-1/VEGF, EGFR mutation - Read more

Mentari Therapeutics raises $200M private placement to advance migraine prevention biologics pipeline
Migraine, biologics, neurological, clinical-stage - Read more

Tikva Allocell closes $8M Series A to advance EBV-specific T-cell therapy for solid tumors
Cell therapy, oncology, allogeneic, solid tumors, preclinical - Read more

Transcripta Bio raises $24M in funding for AI-powered neurological drug discovery expansion
AI-driven, neurological, rare disease, drug discovery, transcriptomics - Read more

BeOne Medicines commits $300M to New Jersey manufacturing expansion, adding small molecule capabilities and 120 jobs
Small molecule, oncology, operational, major transaction - Read more

NIH leads $1.2B Bio Genesis Mission to halve biomedical discovery timelines using AI
Artificial intelligence, chronic disease, drug discovery, major investment - Read more

FDA Modernization Act 3.0 passes House, directing agency to update animal testing regulations
Preclinical testing, drug development, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Roche Diagnostics posts muted 3% sales growth in H1 2026 amid China pricing reform headwinds
Diagnostics, healthcare pricing reform, financial, operational - Read more

Roche reports Vabysmo US sales slump returns, offset by reduced biosimilar headwinds and pipeline hopes
Small molecule, ophthalmology, oncology, revenue impact, competitive- Read more

Clinuvel Pharmaceuticals relocates headquarters to US, cuts up to 20% of workforce in strategic restructuring
Small molecule, rare disease, operational, cost reduction, strategic - Read more

FDA flags Sanofi emails for misleadingly promoting Beyfortus as broad RSV preventative, demands immediate action
Monoclonal antibody, infectious disease, regulatory, operational - Read more

FDA issues warning letters to Almon Healthcare and Shimoga Chemicals over data, sanitation violations
Small molecule, infertility, operational, regulatory - Read more

Roche drops RG6382 TCE for lupus but confirms continued autoimmune cell therapy development plans
T-cell engager, autoimmune, strategic, pipeline - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here